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Abstract
Introduction: Chagas disease remains a major cause of mortality in several countries of Latin America and has become a
potential public health problem in non-endemic countries as a result of migration flows. Cardiac involvement represents the
main cause of mortality, but its diagnosis is still based on nonspecific criteria with poor sensitivity. Early identification of
patients with cardiac involvement is desirable, since early treatment may improve prognosis. This study aimed to assess the
role of diastolic dysfunction, abnormal myocardial strain and elevated brain natriuretic peptide (BNP) in the early
identification of cardiac involvement in Chagas disease.
Methodology/Principal Findings: Fifty-four patients divided into 3 groups—group 1 (undetermined form: positive serology
without ECG or 2D-echocardiographic abnormalities; N=32), group 2 (typical ECG abnormalities of Chagas disease but
normal 2D-echocardiography; N=14), and group 3 (regional wall motion abnormalities, left ventricular [LV] end-diastolic
diameter .55 mm or LV ejection fraction ,50% on echocardiography; N=8)—and 44 control subjects were studied.
Patients with significant non-cardiac diseases, other heart diseases and previous treatment with benznidazol were excluded.
The median age was 37 (20–58) years; 40% were men. BNP levels, longitudinal and radial myocardial strain and LV diastolic
dysfunction increased progressively from group 1 to 3 (p for trend ,0.01). Abnormal BNP levels (.37 pg/ml) were noted in
0%, 13%, 29% and 63% in controls and groups 1 to 3, respectively. Half of patients in the undetermined form had impaired
relaxation patterns, whereas half of patients with ECG abnormalities suggestive of Chagas cardiomyopathy had normal
diastolic function. In group 1, BNP levels were statistically higher in patients with diastolic dysfunction as compared to those
with normal diastolic function (27626 vs. 1168 pg/ml, p=0.03).
Conclusion/Significance: In conclusion, the combination of diastolic function and BNP measurement adds important
information that could help to better stratify patients with Chagas disease.
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Introduction
Chagas disease, a major cause of morbidity and mortality in
several countries of Latin America [1], has become a potential
public health problem in countries where the disease is not
endemic as a result of migration flows [2,3,4]. Chagas cardiomy-
opathy is the most serious form of the chronic phase of the disease
and represents the major cause of mortality in these patients. For
this reason, accurate diagnosis of cardiac involvement is critical.
However, Chagas disease remains a neglected disease [5] and the
diagnosis of Chagas cardiomyopathy is still based on simple and
nonspecific criteria including an increased cardiothoracic ratio
(.0.5) or ECG abnormalities such as complete right bundle-
branch block, left anterior hemiblock, complete left bundle-branch
block, as well as other conduction and rhythm disturbances [6,7].
Echocardiography refined the diagnosis of Chagas cardiomyopa-
thy, and regional wall motion abnormalities, reduced left
ventricular ejection fraction (LVEF) ,50% and increased left
ventricular (LV) end-diastolic diameter .55 mm are now included
as diagnostic criteria in some publications [8,9]. In spite of that,
the sensitivity of these parameters is far from perfect and they may
indeed misclassify patients with early myocardial involvement into
www.plosntds.org 1 September 2010 | Volume 4 | Issue 9 | e826the undetermined form, as conventional 2D echocardiography
only detects advanced myocardial involvement. On the other
hand, patients without cardiac disease but having one of the
described as typical but unspecific ECG findings could be
considered to have Chagas cardiomyopathy. Therefore, a more
accurate classification model, particularly to identify patients with
early cardiac involvement from the undetermined form would be
desirable, since an early treatment and closer follow-up might be
beneficial on these patients [8].
Analysis of diastolic function by echocardiography, cardiac
magnetic resonance (CMR) and several biomarkers, including
brain natriuretic peptide (BNP) and inflammation markers, have
emerged as useful tools in the diagnosis and monitoring of heart
failure in different conditions. In fact, BNP has recently been
included in the guidelines for the diagnosis and management of
congestive heart failure [10]. Comprehensive evaluation of
diastolic dysfunction and myocardial strain imaging has provided
more accuracy and sensitivity to detect early myocardial
involvement in different cardiomyopathies [11,12]. However,
these methods have been seldom utilized in characterizing patients
with established Chagas cardiomyopathy [13,14,15], and its role
in the identification of cardiac involvement in the earlier phases of
the disease is unclear [16,17,18].
We conducted a prospective study aimed to analyze the added
value of different techniques in identifying cardiac involvement in
the undetermined stage of Chagas disease. Diastolic function,
natriuretic peptide and inflammatory markers levels in different
phases of the disease were measured and correlated with
longitudinal and radial myocardial strain and delayed enhance-
ment on CMR to find out their value in improving the
stratification of patients with Chagas disease.
Methods
Study Population
A cross-sectional analysis was performed in a prospective cohort
of consecutive adult patients evaluated at our Institution from
January 2008 to June 2009. Diagnosis of Chagas disease was based
on a clinical record compatible with the epidemiology of the
disease (individuals from endemic zones of Chagas disease) and
microbiologic diagnosis by any combination of at least two positive
commercial serological tests using different antigens: ELISA using
a T. cruzi lysate (Ortho-Clinical DiagnosticsH), ELISA with
recombinant antigens (BioELISA ChagasH, Biokit S.A.) and
indirect immunofluorescence (Inmunofluor Chagas, Biocientifi-
caH). In an attempt to avoid factors that could have an effect on
diastolic function, myocardial strain, natriuretic peptides or
inflammatory markers levels, patients with severe non-cardiac
diseases, prior diagnosis of heart disease from other etiology
(ischemic, hypertensive or alcoholic), hypertension, diabetes
mellitus, active infections by other causal agent or previous
treatment with benznidazol were excluded. All patients gave
written consent for inclusion. The research protocol was approved
by the Ethics Committee of our institution.
Patients meeting the inclusion criteria were categorized into 4
groups: Group 0 (control group, subjects from endemic areas with
negative serology for Chagas disease); Group 1 (patients in the
undetermined form of Chagas disease defined as those with
positive serology of Chagas disease without any abnormal ECG
finding, normal LV dimensions and LV global and regional
systolic function with conventional 2D echocardiography); Group
2 (patients with typical ECG abnormalities of cardiac involvement
by Chagas disease such as complete right bundle-branch block
and/or left anterior hemiblock, complete left bundle-branch block,
ventricular premature beats, primary abnormalities of ventricular
repolarization, electrically inactive zones, low voltage QRS, sinus
bradycardia ,50 beat/min, advanced atrioventricular block or
cardiac pacemaker, but normal LV dimensions and global and
regional systolic function by 2D-echocardiography); and Group 3
(patients with Chagas cardiomyopathy with any regional wall
motion abnormality and/or LV end-diastolic diameter .55 mm
and/or LVEF ,50% by 2D-echocardiography).
Clinical examination, blood analysis including ions, creatinin,
inflammatory markers and natriuretic peptides levels as well as a
comprehensive 2D-echocardiogram with diastolic function and
myocardial strain analysis were obtained from all patients. CMR
studies were performed in an unselected sample of patients with
Chagas disease (Groups 1–3).
Biochemical measurements
Measurements of plasmatic levels of endothelin 1, tumor
necrosis factor-a (TNFa), interleukin 6 (IL-6), atrial natriuretic
peptide (ANP) and BNP levels was carried out through peripheral
venous puncture, after a 30 minutes rest, and quantified using
commercially available kits. BNP levels were measured using a
fully automated two-site sandwich BNP immunoassay on an Advia
Centaur (Siemens Diagnostics, Zurich, Switzerland). Minimum
sensitivity and upper limit of normal values are 2 and 37 pg/ml
respectively for the BNP assay. The precision of this technique is
1.8–4.3%.
Imaging techniques
Echocardiographic studies were performed with a commercially
available system (VIVID 7, General Electrics; Milwaukee, WI).
Images were digitally stored for later off-line analysis with a
commercial software package (EchoPac, General Electrics;
Milwaukee, WI). LV volumes and LVEF were calculated using
the modified Simpson rule (biplane method). Left atrium area was
measured at the end-ventricular systole excluding the confluences
of the pulmonary veins and the left atrium appendage. LV
volumes and left atrium area were indexed to body surface area.
Analysis of diastolic function was performed evaluating the mitral
Author Summary
Chagas disease remains a major cause of morbidity and
mortality in several countries of Latin America and has
become a potential public health problem in countries
where the disease is not endemic as a result of migration
flows. Cardiac involvement represents the main cause of
mortality, but its diagnosis is still based on nonspecific
criteria with poor sensitivity. Early identification of patients
with cardiac damage is desirable, since early treatment
may improve prognosis. Diastolic dysfunction and elevat-
ed brain natriuretic peptide levels are present in different
cardiomyopathies and in advanced phases of Chagas
disease. However, there are scarce data about the role of
these parameters in earlier forms of the disease. We
conducted a study to assess the diastolic function, regional
systolic abnormalities and brain natriuretic peptide levels
in the different forms of Chagas disease. The main finding
of our investigation is that diastolic dysfunction occurs
before any cardiac dilatation or motion abnormality. In
addition, BNP levels identify patients with diastolic
dysfunction and Chagas disease with high specificity. The
results reported in this study could help to early diagnose
myocardial involvement and better stratify patients with
Chagas disease.
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deceleration time of the E wave (DT); the pulmonary vein flow
and the mitral annulus velocities with Doppler Tissue Imaging
(Em and Am). Patients were classified according to diastolic
function patterns (normal, impaired relaxation or stage I,
pseudonormal or stage II and restrictive pattern or stage III)
following current recommendations [19]. The ratio of early
diastolic mitral flow velocity to early diastolic mitral annulus
velocity (E/Em) was used as a surrogate of LV filling pressures. LV
segmental myocardial longitudinal 2D-strains were acquired from
two and four-chamber apical views and radial strains from the
parasternal short axis view at the level of the papillary muscles.
Averages of longitudinal and radial strains were obtained by
dividing the sum of all segmental strains by the number of
analyzed segments. Images were optimized to obtain a frame rate
.50 fps.
CMR studies were performed using a 1.5 T clinical scanner
(Signa CV HDxt, General Electric, Milwaukee WI). Functional
assessment was studied with a standard cine steady-state free
precession sequence and delayed-enhanced images were acquired
using a gradient-echo segmented inversion recovery technique, 10
minutes after intravenous administration of gadodiamide at a dose
of 0.2 mmol/Kg (Omniscan, GE Healthcare, Madrid). LV end-
diastolic, end-systolic volumes and LVEF were calculated using
Mass 4.0.1 software analysis (MEDIS, The Netherlands). All
echocardiographic and CMR analyses were performed by
experienced independent observers blinded to BNP measurements
and clinical data.
Statistical analysis
Continuous baseline variables were expressed as mean6SD or
median (interquartile range) values depending on normality
assessed by the Shapiro-Wilks test. Categorical variables were
expressed as total number (percentages) and compared between
groups using Chi-square test or Fisher’s test. Differences in
continuous variables were analyzed using either ANOVA test or
Kruskall Wallis test depending on variable distribution. Post-hoc
analysis using either T-test or Wilcoxon test corrected by
Bonferroni method was carried out to detect differences between
each pair of groups. Trends in continuous variable changes across
Chagas’s disease severity and diastolic function impairment were
analyzed using either ANOVA test for trend or Jonckheere-
Terpstra test. Correlations between natriuretic peptides and LV
volumes and LVEF were assessed using Pearson coefficient.
Receiver-operating characteristic (ROC) curves were constructed
to estimate the accuracy of BNP and ANP to detect any grade of
diastolic dysfunction. Statistical analysis was performed with SPSS
15.0H.
Results
A total of 98 consecutive subjects were included. Median age
was 37 (range 20 to 58) years and 40% were men. There were 44
subjects in Group 0, 32 patients in Group 1, 14 in group 2, and 8
patients in group 3. Clinical characteristics, hemodynamic data,
and levels of inflammatory markers and natriuretic peptides are
shown in Table 1. Creatinin and sodium plasmatic levels were
normal for all patients. Only two patients were under pharmaco-
logical treatment: one patient in group 1 was treated with
betablockers and one patient in group 3 was under angiotensin
converting enzyme inhibitors. There were no differences in clinical
and hemodynamic characteristics between groups except for the
New York Heart Association (NYHA) functional class. The
majority of patients were in NYHA functional class I; no patient
had NYHA functional class III or IV. TNFa levels were higher in
group 1 as compared to group 0 and a significant trend towards
increasing levels was observed according worsening clinical forms
Table 1. Demographic and hemodynamic characteristics and blood markers of control individuals and patients in the
undetermined and cardiac forms.
Variable
Group 0 Control
(N=44)
Group 1 Undetermined
(N=32)
Group 2 ECG findings
(N=14)
Group 3 Abnormal
echo (N=8) P P for trend
Age (years) 34.0 (11.5) 36.8 (14.6) 42.7 (17.4) 40.9 (8.6) 0.02 ,0.01
Gender (male) 18 (41%) 13 (34%) 6 (43%) 4 (50%) 0.80 NA
Smoking habit 6 (14%) 2 (6%) 1 (7%) 2 (25%) 0.42 NA
Hypercholesterolemia 2 (5%) 2 (6%) 2 (14%) 1 (13%) 0.60 NA
Systolic BP (mmHg) 106611 113614 113615 113614 0.09 0.05
Diastolic BP (mmHg) 66686 9 610 70611 68616 0.31 0.15
Heart rate (bpm) 60.0 (9.0) 65.0 (10.0) 60.0 (9.0) 56.0 (23.0) 0.31 0.94
NYHA FC II 0 (0%) 0 (0%) 2 (14%) 3 (38%) 0.01 NA
Endothelin (pmol/L) 6.8 (2.4) 6.3 (3.2) 6.0 (2.4) 6.7 (5.0) 0.35 0.66
IL6 (pg/ml) 1.763.2 11.3628.3 0.060.0 22.2654.0 0.09 0.12
TNFa (pg/ml) 3.0 (6.5) 7.0 (5.8)* 7.0 (4.0) 9.5 (7.3) ,0.01 ,0.01
BNP (pg/ml) 10.3 (10.2) 12.3 (17.1) 15.3 (31.0) 43.6 (190.0)*{ ,0.01 ,0.01
BNP.37 pg/ml 0 (0%) 4 (13%) 4 (29%) 5 (63%) ,0.01 NA
ANP (pg/ml) 23.8 (11.0) 26.5 (15.0) 28.0 (11.3)* 54.0 (39.8)*{ ,0.01 ,0.01
Continuous variables are expressed as mean 6 standard deviation or median (interquartile range); categorical variables are expressed as number of patients (%).
BP: blood pressure; NYHA FC= New York Heart Association functional class; TNFa: tumour necrosis factor alpha; BNP: brain natriuretic peptide; ANP: atrial natriuretic
peptide. NA: non applicable (categorical variables); P= p value between groups; P for trend: p value for a trend in continuous variable changes across Chagas’s disease
severity.
*Statistically significant differences versus group 0.
{Statistically significant differences versus group 1.
doi:10.1371/journal.pntd.0000826.t001
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noted in 0%, 13%, 29% and 63% of patients in groups 0, 1, 2 and
3, respectively. BNP and ANP levels in group 3 were significantly
elevated as compared to those in groups 0 and 1. There were no
statistically significant differences in IL6 and endothelin 1 levels
between groups. IL6 levels were undetectable in 68% of patients.
Echocardiographic data regarding LV volumes, LVEF, LV
myocardial strains and diastolic function are shown in Table 2.
Patients in the undetermined form (group 1) showed no differences
in LV dimensions or global LVEF as compared to the control
group but had significantly reduced Em and lengthened DT
(0.1460.03 m/s vs. 0.1660.03 m/s and 238.5 ms vs. 200 ms,
respectively; p,0.001 for both).
When patients were classified according to the diastolic function
pattern, 50% of patients in groups 1 and 2 had an impaired
relaxation pattern. On contrast, every patient in group 3 had a
certain degree of diastolic dysfunction (Table 3). Two (5%) subjects
in group 0 had impaired relaxation pattern. Natriuretic peptides
and LV myocardial strain averages were progressively different as
diastolic dysfunction severity increased (p for trend ,0.01)
(Table 4). The accuracy of BNP and ANP to detect any grade
of diastolic dysfunction, as assessed by the area under the ROC
curve, was 0.73, 95%CI 0,60–0.85 for BNP and 0.70; 95%CI 0.58
– 0.81 for ANP. In addition, both BNP and ANP significantly
correlated with LV end-diastolic volumes (r=0.35; p=0.001 and
r=0.26; p=0.013, respectively), LV end-systolic volumes
(r=0.44; p,0.001 and r=0.36; p,0.001 respectively) and LVEF
(r=20.44; p,0.001 and r=20.44; p,0.001, respectively).
When only patients in the undetermined form of the disease
(group 1) were considered, BNP levels were higher in patients with
diastolic dysfunction compared to those with normal diastolic
pattern (27626 versus 1168 pg/ml, respectively, p=0.03). A
similar result was obtained in group 2, thus, a trend towards
increasing BNP levels was observed from normal diastolic pattern
to abnormal relaxation and pseudonormal pattern (1164, 37636
and 4163, pg/ml respectively, p=0.06). The areas under the
ROC curves for BNP and ANP to detect mild diastolic dysfunction
in patients in the undetermined form were 0.69; 95%CI 0,49–0.89
for BNP and 0.62; 95%CI 0.43–0.82 for ANP. Additionally, every
patient with abnormally high levels of BNP (.37 pg/ml) had
diastolic dysfunction (Figure 1).
A CMR was performed in 21 Chagas disease patients, 7 patients
in each group (groups 1–3) according to the standard classification
[20,21]. Two (28%) patients in group 1 (Figure 2), 1 (14%) patient
in group 2 and 3 (43%) patients in group 3 had gadolinium
delayed enhancement compatible with scar or fibrosis. However,
when these patients were classified according to the diastolic
function pattern, none with normal diastolic function had delayed
enhancement, whereas 40% of patients with impaired relaxation
pattern and 50% with pseudonormal pattern showed delayed
enhancement (Figure 3).
Discussion
The main finding of our investigation is that diastolic
dysfunction occurs before any LV dilatation, regional or global
systolic abnormalities or significant increased filling pressures as
assessed by E/Em ratio. In this regard, we found significant
reduction in Em and lengthening in DT in patients in the
undetermined form compared to control individuals, in spite of
preserved LV volumes and systolic function. The fact that all the
rest of the echocardiographic measurements remained similar in
both the undetermined form and control individuals, suggests that
Em and DT could be the most sensitive echocardiographic
parameters to detect cardiac involvement by Chagas disease. In
addition, BNP levels identify patients with diastolic dysfunction
among those in the undetermined form of Chagas disease with
high specificity. The study also confirmed the fact that as the
disease progresses from the undetermined form to Chagas
Table 2. Echocardiographic parameters of control individuals and patients in the undetermined and cardiac forms.
Variable
Group 0 Control
(N=44)
Group 1 Undetermined
(N=32)
Group 2 ECG findings
(N=14)
Group 3 Abnormal
echo (N=8) P P for trend
LVEDV (ml/m
2) 59.5 (13.2) 56.2 (14.3) 68.1 (13.8) 93.7 (25.4)*{{ ,0.01 0.02
LVESV (ml/m
2) 23.0 (7.4) 21.7 (6.6) 28.4 (8.7) 52.0 (15.1)*{{ ,0.01 0.02
LA (cm/m
2) 7.8 (2.1) 8.6 (2.8) 9.1 (1.9) 10.8 (5.2)* ,0.01 ,0.01
LVEF (%) 64.5 (5.0) 65.0 (4.8) 60.0 (9.0) 41.0 (12.5)*{{ ,0.01 ,0.01
E (m/s) 0.8560.13 0.7860.17 0.7660.11 0.7260.17 0.05 ,0.01
A (m/s) 0.51 (0.2) 0.60 (0.2) 0.59 (0.3) 0.50 (0.26) 0.30 0.51
Em (m/s) 0.1660.03 0.1460.03* 0.1260.04* 0.0960.04*{ ,0.01 ,0.01
Am (m/s) 0.09 (0.04) 0.09 (0.03) 0.09 (0.04) 0.08 (0.04) 0.60 0.58
E/Em 5.0 (1.9) 5.9 (2.0) 7.1 (3.4) 7.9 (3.9)*{ ,0.01 ,0.01
DT (ms) 200.0 (45.0) 238.5 (62.0)* 251.5 (140.0)* 284.5 (172.7)* ,0.01 ,0.01
Average LS (%) 19.3 (3.8) 19.3 (2.9) 17.1 (5.0) 15.8 (6.9)*{{ ,0.01 ,0.01
Average RS (%) 49.3 (22.5) 39.8 (36.2) 40.2 (22.8) 16.0 (13.2)*{{ ,0.01 ,0.01
Continuous variables are expressed as mean 6 standard deviation or median (interquartile range); categorical variables are expressed as number of patients (%).
LVEDV: left ventricular end-diastolic volume indexed to body surface area; LVESV: left ventricular end-systolic volume indexed to body surface area; LA: left atrium area
indexed to body surface area; LVEF: left ventricular ejection fraction; E: early diastolic mitral flow velocity; A: late diastolic mitral flow velocity; Em: early mitral annulus
diastolic tissue velocity; Am: late mitral annulus diastolic tissue velocity; E/Em: ratio of early diastolic mitral flow velocity to early diastolic mitral annulus velocity; DT:
deceleration time of the E wave; LS: myocardial longitudinal strain; RS: myocardial radial strain. P= p value between groups; P for trend: p value for a trend in
continuous variable changes across Chagas’s disease severity.
*Statistically significant differences versus group 0.
{Statistically significant differences versus group 1.
{Statistically significant differences versus group 2.
doi:10.1371/journal.pntd.0000826.t002
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enlargement of LV volumes and a deterioration of global LV
function, diastolic function deteriorates. This is supported also by
the fact that global LV strain, both longitudinal and radial, also
progressively decreases along with diastolic function impairment,
suggesting the existence of myocardial damage, despite preserved
LVEF.
Previous studies analyzing diastolic function in the undeter-
mined form of Chagas disease have shown conflicting results (15–
21). Barros et al. were the first to report early LV diastolic
dysfunction in patients in the undetermined form of Chagas
disease as they demonstrated a lengthening of DT and isovolumic
relaxation time [16]. Cianciulli et al. similarly observed that
transmitral Doppler flow allowed to identify early abnormalities of
diastolic function in patients with normal ECG and conventional
2D-echocardiogram [17]. On the other hand, Pazin-Filho et al.
also focused on patients in the undetermined form and showed
that patients with normal global and segmental LV systolic
function by 2D echocardiography did not show any abnormality
of diastolic function [18]. However, in a meticulous evaluation of
this small study a trend for higher LA volumes, DT lengthening
and Em reduction could be observed among groups, and
therefore, an insufficient statistical power might have contributed
to the negative result.
Despite being only performed in a small subgroup of patients,
the results of CMR also sustain that diastolic dysfunction may be
the first manifestation of myocardial involvement, before systolic
dysfunction occurs as it happens in other cardiomyopathies.
Therefore, the comprehensive analysis of diastolic dysfunction
could be more sensitive in terms of early diagnosis of myocardial
involvement compared to the standard classification as it was
shown that some patients with normal ECG and normal
conventional 2D-echocardiography had myocardial fibrosis de-
tected by delayed enhancement, whereas no patient with normal
diastolic function had enhancement on CMR. A prior study
showed that delayed enhancement in CMR can be present in up
to 20% of patients who are in the undetermined form of the
disease [22], suggesting that this technique has an extended value
for the diagnosis in early stages of cardiac involvement. However,
CRM availability is limited particularly in areas where Chagas
disease is endemic. The association between a normal diastolic
function by echo and absence of fibrosis on CMR has to be
confirmed in larger series.
Nevertheless, although diastolic function analysis seems to have
a high sensitivity, it has to be acknowledged that the complexity of
diastolic dysfunction measurements may preclude its use in large
populations, especially in underdeveloped geographical areas. In
this regard, the initial screening with BNP determination could be
helpful, especially with the use of simplified, point-of-care kits. In
fact, every patient with abnormally high BNP levels had diastolic
dysfunction in our study (Figure 1).
Natriuretic peptides have been shown to be involved in the
pathogenesis of Chagas disease in animal experiments [23,24] and
some clinical studies have reported that BNP levels are increased
in Chagas cardiomyopathy [25,26,27] and correlates with
prognosis [28]. Ribeiro et al. demonstrated a high specificity with
moderate sensitivity for BNP to detect LVEF#40% in infected
patients with an abnormal ECG or chest X-ray [25]. In a second
study, the same group reported that BNP levels correlated with LV
dimensions and LVEF in patients with Chagas disease and also
that patients with mild degree of cardiac dysfunction, defined as no
more that minor alterations in their echocardiography, had
intermediate BNP levels compared to control individuals and
patients in the cardiac form of the disease [27]. In a third study,
Table 3. Diastolic function in patients with undetermined and cardiac forms of Chagas disease.
Group 1 Undetermined
(N=32)
Group 2 ECG
findings (N=14)
Group 3 Abnormal echo
(N=8)
Normal (N=23) 16 (50%) 7 (50%) 0 (0%)
Impaired relaxation (N=25) 16 (50%) 5 (36%) 4 (50%)
Pseudonormal (N=6) 0 (0%) 2 (14%) 4 (50%)
Data are expressed as number of patients (%).
doi:10.1371/journal.pntd.0000826.t003
Table 4. Serum and myocardial strain according to diastolic function classification in patients with Chagas disease.
Normal (N=23) Impaired relaxation (N=25) Pseudonormal (N=6) P P for trend
BNP (pg/ml) 10.1 (9.2) 18.7 (39.3) { 43.4 (245.0) * ,0.01 ,0.01
ANP (pg/ml) 26.0 (12.0) 30.0 (25.0) 55.0 (69.8) * ,0.01 ,0.01
Edothelin1 (pmol/L) 5.7 (4.2) 6.7 (2.3) 7.3 (6.3) 0.15 0.05
IL6 (pg/ml) 266.1 14.0632.7 29.0664.8 0.16 0.06
TNFa (pg/ml) 7.0 (4.2) 6.5 (6.0) 10.0 (9.5) 0.71 0.47
Average LS (%) 18.4 (3.0) 18.7 (4.6) 14.4 (6.5) * 0.04 ,0.01
Average RS (%) 40.2 (37.8) 31.2 (34.1) 14.8 (16.5) * 0.01 ,0.01
Data are expressed as mean 6 standard deviation or median (interquartile range).
BNP: brain natriuretic peptide; ANP: atrial natriuretic peptide; TNFa: tumour necrosis factor alpha. P= p value between groups; P for trend: p value for a trend in
continuous variable changes across diastolic dysfunction impairment.
*Statistically significant differences between pseudonormal pattern and Normal pattern.
{Statistically significant differences between impaired relaxation pattern and Normal pattern.
doi:10.1371/journal.pntd.0000826.t004
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plasmatic levels and ECG vs. the standard strategy (ECG and
chest X-ray) to detect LVEF #40% and demonstrated a
significant improvement in specificity although the new strategy
had less sensitivity [26]. However, even though the correlation
between BNP levels and systolic dysfunction in Chagas disease has
Figure 1. Distribution of patients according to the conventional 2D-echocardiography, ECG and diastolic function and prevalence
of pathologic levels of BNP (% of patients). Echo= conventional 2D-echocardiography; ECG= electrocardiogram; DF= diastolic function
(assessed by echocardiography); BNP= Brain natriuretic peptide. Normal echo means normality in LV dimensions and LV global and regional systolic
function assessed with conventional 2D echocardiography.
doi:10.1371/journal.pntd.0000826.g001
Figure 2. Example of a patient in the undetermined form of Chagas disease with delayed enhancement on cardiac magnetic
resonance and abnormal diastolic function. Short axis delayed enhanced CMR images (panels A & B) showing focal linear hyperenhancement in
the basal inferolateral segment (red arrows). Panels C and D depict Doppler mitral inflow and myocardial tissue velocity imaging pattern consistent
with impaired diastolic dysfunction in the same patient.
doi:10.1371/journal.pntd.0000826.g002
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diastolic function in Chagas disease [14,29]; indeed, all of them
have been done in patients in the cardiac form of Chagas disease.
Barbosa et al [14] evaluated 59 patients with dilated cardiomy-
opathy due to Chagas disease and reported a marked elevated
concentration of the amino-terminal portion proBNP specifically
in patients with a restrictive diastolic pattern. Oliveira et al [29]
evaluated 36 patients, all of them with diffuse or segmental
ventricular motion abnormalities, and described a significant
correlation between BNP and E/E’ ratio in the inferior wall. To
our knowledge there are no studies that have specifically assessed
the association between BNP and diastolic function in patients in
the undetermined form. In our population, the accuracy of BNP to
detect any degree of diastolic dysfunction was good (area under
curve of 0.73); additionally, the ability to detect mild diastolic
dysfunction in the group of patients in the undetermined form was
also good (area under the curve of 0.69). The specificity of BNP
levels .37 pg/ml to detect mild diastolic dysfunction in patients in
the undetermined form of Chagas disease was 100%. The power
of ANP levels to detect diastolic dysfunction was slightly inferior’’.
Different from ANP, BNP is mainly secreted in the ventricles in
response to wall stress, ischemia or fibrosis. Indeed, myocardial
fibrosis has been described to strongly trigger BNP synthesis [30].
Chagas cardiomypathy is a predominately fibrogenetic cardiomy-
opathy. Cardiac fibrosis is evident even in early stages of the
disease [22,31]. This fact might explain why BNP levels could be
elevated even in patients with normal NYHA functional class,
normal LVEF and ventricular filling pressures, and supports the
idea that BNP levels measurement could be useful to early detect
cardiac involvement in Chagas disease. Enhanced fibrosis,
compared with other cardiomyopathies, could also explained
higher BNP levels in patients with Chagas disease as compared to
patients with cardiac disease of different etiologies in the same
NYHA functional class [32].
Our study also aimed to assess the plasmatic levels of TNFa,
IL6 and endothelin 1, in patients with different clinical forms of
Chagas cardiomyopathy. These biomarkers have been described
to be elevated in Chagas cardiomyopathy [33,34,35]. We found
statistically significant elevated levels of TNFa in patients in the
undetermined form as compared to control individuals and a
significant trend towards increasing levels was observed along
clinical severity groups. Our finding is in concordance with
previously published literature suggesting heart inflammation in
patients with Chagas disease even in the absence of heart failure.
Talvani et al [35] had previously reported higher TNFa levels in
patients with severe Chagas cardimyopathy; in this study although
TNFa levels were slightly higher in patients in the undetermined
form as compared to those in healthy individuals, no statistically
significant differences were reached. Similarly, in our study, a
trend towards greater IL6 levels could be also observed along with
progressive clinical severity and diastolic function impairment.
However, as this measurement was undetectable in a significant
proportion of patients, its interpretation is limited. The use of
high-sensitivity kits for IL6 detection could be valuable in this
context. Finally, our study failed to demonstrate differences in
plasmatic levels of endothelin 1 in the different forms of Chagas
disease. A privious study reported elevated endothelin plasmatic
levels in patients with Chagas cardiomyopathy [33]. However, in
this study seropositive patients had similar endothelin plasmatic
levels than control individuals, and the group of patients in the
undetermined form had even lower levels than controls.
Therefore, the usefulness of plasmatic measurement of endothelin
is not clear and more studies are required to clarify its role in the
clinical evaluation of patients with Chagas disease.
The main limitation of our study is its cross-sectional design
and, consequently progression of cardiomyopathy could not be
evaluated. Longitudinal studies in Chagas disease are difficult due
to the slow progression of the disease and the frequent change of
residency that particularly patients who live in non-endemic areas
have, making follow-up difficult.
In conclusion, the initial screening with measurement of BNP,
an easy test with high specificity for LV damage, combined with a
comprehensive analysis of diastolic function that contributes with
high sensitivity seems to be a more accurate strategy to early
diagnose LV involvement in Chagas disease. Our findings could
help to better stratify patients with Chagas disease. The association
between normal diastolic function, normal BNP levels, absent
fibrosis on CMR and no progression of the disease warrants
confirmation in larger and prospective longitudinal studies. Also,
new studies are required to demonstrate that early treatment and
Figure 3. Delayed enhancement on CMR (observed cases/N) in Chagas diseases patients. A Conventional classification. B Classification
based on diastolic function. CMR= Cardiac Magnetic Resonance; ECG= electrocardiogram; Echo= conventional 2D-echocardiography.
doi:10.1371/journal.pntd.0000826.g003
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improve the prognosis in these patients.
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